The clinical results of patients stratified with ARB medication at randomization.

*

ARB: Angiotensin II type I receptor blocker. Percent changes of UACR: calculated by level of UACR at each visit compared to level of baseline. Final value: mean value of UACR at 12 weeks and 16 weeks. Secondary outcome: levels of UACR or UPCR at 16 weeks compared to level of baseline. Baseline value: mean value of UACR or UPCR at screening period and randomization period (0 week).